How to buy Immunic stock (IMUX)

Immunic is a biotechnology business based in the US. Immunic shares (IMUX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.31 – a decrease of 8.39% over the previous week. Immunic employs 85 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Immunic stock

Buy Immunic stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Immunic stock price (NASDAQ: IMUX)

Use our graph to track the performance of IMUX stocks over time.

Immunic shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$1.31
52-week range	$0.95 - $2.11
50-day moving average more info button	$1.52
200-day moving average more info button	$1.34
Wall St. target price	$12.75
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.45

Is it a good time to buy Immunic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunic price performance over time

Historical closes compared with the close of $1.34 from 2024-10-28

1 week (2024-10-23)	-6.29%
1 month (2024-09-30)	-18.79%
3 months (2024-07-30)	-4.29%
6 months (2024-04-30)	6.35%

1 year (2023-10-30)	32.02%
2 years (2022-10-28)	-24.29%
3 years (2021-10-29)	9.32
5 years (2019-10-30)	8.55

Immunic financials

Gross profit TTM	$0
Return on assets TTM	-66.8%
Return on equity TTM	-143.47%
Profit margin	0%
Book value	$0.71
Market Capitalization more info button	$128.8 million

TTM: trailing 12 months

Immunic share dividends

We're not expecting Immunic to pay a dividend over the next 12 months.

Have Immunic's shares ever split?

Immunic's shares were split on a 1:40 basis on 14 April 2019 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immunic shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Immunic shares which in turn could have impacted Immunic's share price.

Immunic share price volatility

Over the last 12 months, Immunic's shares have ranged in value from as little as $0.945 up to $2.11. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunic's is 1.843. This would suggest that Immunic's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Immunic overview

Immunic, Inc. , a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. .

Frequently asked questions

null
What percentage of Immunic is owned by insiders or institutions?
Currently 3.34% of Immunic shares are held by insiders and 62.489% by institutions. How many people work for Immunic?
Latest data suggests 85 work at Immunic. When does the fiscal year end for Immunic?
Immunic's fiscal year ends in December. Where is Immunic based?
Immunic's address is: 1200 Avenue of the Americas, New York, NY, United States, 10036 What is Immunic's ISIN number?
Immunic's international securities identification number is: US4525EP1011 What is Immunic's CUSIP number?
Immunic's Committee on Uniform Securities Identification Procedures number is: 4525EP101